Previous 10 | Next 10 |
2024-05-14 10:00:29 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Health...
2024-05-13 17:06:07 ET Gainers: Harrow ( HROW ) +15% . Fulcrum Therapeutics ( FULC ) +7% . Allogene Therapeutics ( ALLO ) +6% . Infinera Corporation ( INFN ) +6% . Voyager Therapeutics ( VYGR ) +5% . Losers: Akoya BioScie...
2024-05-13 16:19:50 ET More on Harrow Health Harrow: Merits A Buy On Sales Potential Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom Harrow, Inc. (HROW) Q4 2023 Earnings Call Transcript Harrow Health Q4 2023 Earnings Preview Seekin...
First Quarter 2024 and Recent Selected Highlights: Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable fo...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing p...
2024-05-12 17:35:55 ET Major earnings expected after the bell on Monday include: Petróleo Brasileiro S.A. - Petrobras ( PBR ) Lithium Americas (Argentina) Corp. ( LAC ) StoneCo Ltd. ( STNE ) Inovio Pharmaceuticals ( INO ) Alcon ( ALC ) ...
2024-05-12 17:35:00 ET More on Harrow Health Harrow: Merits A Buy On Sales Potential Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom Harrow, Inc. (HROW) Q4 2023 Earnings Call Transcript Harrow Health Q4 2023 Earnings Preview Seekin...
2024-05-02 12:20:24 ET Summary Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expected to drive significant revenue for Harrow. Ve...
2024-05-02 04:42:01 ET Summary Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headac...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 10:00:07 ET Chase Knickerbocker from Craig-Hallum issued a price target of $30.00 for HROW on 2024-06-21 08:28:00. The adjusted price target was set to $30.00. At the time of the announcement, HROW was trading at $19.93. The overall price target consensus is a...
Harrow Health, Inc. (NASDAQ: HROW) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 13.77% on the day to $20.08. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an op...